The outbreak of the novel SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) responsible for coronavirus disease 2019 (COVID-19) has developed into an unprecedented global pandemic. Clinical investigations in patients with COVID-19 has shown a strong upregulation of cytokine and interferon production in SARS-CoV2- induced pneumonia, with an associated cytokine storm syndrome. Thus, the identification of existing approved therapies with proven safety profiles to treat hyperinflammation is a critical unmet need in order to reduce COVI-19 associated mortality. To date, no specific therapeutic drugs or vaccines are available to treat COVID-19 patients. This review evaluates several options that have been proposed to control SARS-CoV2 hyperinflammation and cytokine storm, eincluding antiviral drugs, vaccines, small-molecules, monoclonal antibodies, oligonucleotides, peptides, and interferons (IFNs).

导致 2019 年冠状病毒病 (COVID-19) 的新型 SARS-CoV-2（严重急性呼吸综合征冠状病毒 2）的爆发已发展成为一场前所未有的全球大流行。对 COVID-19 患者的临床研究表明，SARS-CoV2 诱导的肺炎中细胞因子和干扰素的产生强烈上调，并伴有相关的细胞因子风暴综合征。因此，为了降低 COVI-19 相关死亡率，确定现有已批准的具有经过验证的安全性的疗法来治疗过度炎症是一个未得到满足的关键需求。迄今为止，尚无特定的治疗药物或疫苗可用于治疗 COVID-19 患者。本综述评估了控制 SARS-CoV2 过度炎症和细胞因子风暴的几种选择，包括抗病毒药物、疫苗、小分子、单克隆抗体、寡核苷酸、肽和干扰素 (IFN)。